Ulf Grawunder

Ulf is co-founder and CEO of T-CURX. He was also founder and CEO of NBE Therapeutics, a Swiss biotech company developing antibody-drug conjugates (ADCs) for treating cancer patients. NBE was acquired by Boehringer Ingelheim for up to USD 1.4 billion in 2021. Before that, Ulf was co-founder, start-up CEO and later CSO of 4-Antibody, an antibody discovery company, which was acquired by Agenus in 2014. Ulf is Vice-president and Board member of the Swiss Biotech Association and supports several biotechs as advisor and board member. Ulf is a biochemist. He obtained his PhD in Cell Biology from the Basel Institute for Immunology and a Diploma of Technology Entrepreneurship from the University of St. Gallen.